Pacer Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $277M | Sell |
358,633
-39,033
| -10% | -$29.9M | 0.78% | 31 |
|
|
2025
Q4 | $307M | Sell |
397,666
-47,659
| -11% | -$32.4M | 0.78% | 31 |
|
|
2025
Q3 | $250M | Buy |
445,325
+191
| +0% | +$108K | 0.63% | 39 |
|
|
2025
Q2 | $234M | Buy |
445,134
+37,764
| +9% | +$21.1M | 0.58% | 43 |
|
|
2025
Q1 | $258M | Buy |
407,370
+390,374
| +2,297% | +$269M | 0.6% | 42 |
|
|
2024
Q4 | $12.1M | Sell |
16,996
-2,544
| -13% | -$2.13M | 0.03% | 416 |
|
|
2024
Q3 | $20.5M | Buy |
19,540
+3,076
| +19% | +$3.42M | 0.04% | 330 |
|
|
2024
Q2 | $17.3M | Buy |
16,464
+1,434
| +10% | +$1.39M | 0.04% | 351 |
|
|
2024
Q1 | $14.5M | Buy |
15,030
+904
| +6% | +$860K | 0.03% | 367 |
|
|
2023
Q4 | $12.4M | Buy |
14,126
+1,845
| +15% | +$1.52M | 0.04% | 363 |
|
|
2023
Q3 | $10.1M | Buy |
12,281
+1,608
| +15% | +$1.26M | 0.04% | 327 |
|
|
2023
Q2 | $7.67M | Sell |
10,673
-2,362
| -18% | -$1.82M | 0.03% | 449 |
|
|
2023
Q1 | $10.7M | Buy |
13,035
+6,810
| +109% | +$5.14M | 0.05% | 378 |
|
|
2022
Q4 | $4.49M | Sell |
6,225
-256,440
| -98% | -$189M | 0.02% | 458 |
|
|
2022
Q3 | $181M | Buy |
262,665
+41,988
| +19% | +$26.4M | 1.26% | 4 |
|
|
2022
Q2 | $130M | Buy |
220,677
+95,310
| +76% | +$62M | 0.97% | 15 |
|
|
2022
Q1 | $87.6M | Buy |
125,367
+76,354
| +156% | +$48.3M | 0.72% | 19 |
|
|
2021
Q4 | $31M | Buy |
49,013
+38,907
| +385% | +$23.9M | 0.32% | 38 |
|
|
2021
Q3 | $6.12M | Sell |
10,106
-463
| -4% | -$287K | 0.08% | 297 |
|
|
2021
Q2 | $5.9M | Buy |
10,569
+484
| +5% | +$245K | 0.08% | 305 |
|
|
2021
Q1 | $4.77M | Sell |
10,085
-526
| -5% | -$256K | 0.08% | 257 |
|
|
2020
Q4 | $5.13M | Sell |
10,611
-5,218
| -33% | -$2.82M | 0.1% | 163 |
|
|
2020
Q3 | $8.86M | Sell |
15,829
-1,556
| -9% | -$943K | 0.19% | 91 |
|
|
2020
Q2 | $10.8M | Buy |
17,385
+8,625
| +98% | +$4.9M | 0.22% | 79 |
|
|
2020
Q1 | $4.98M | Buy |
8,760
+257
| +3% | +$106K | 0.1% | 77 |
|
|
2019
Q4 | $3.19M | Sell |
8,503
-21,171
| -71% | -$7.12M | 0.14% | 131 |
|
|
2019
Q3 | $8.23M | Buy |
29,674
+2,454
| +9% | +$726K | 0.19% | 92 |
|
|
2019
Q2 | $8.52M | Buy |
27,220
+14,194
| +109% | +$4.73M | 0.21% | 84 |
|
|
2019
Q1 | $5.35M | Buy |
+13,026
| New | +$5.36M | 0.15% | 121 |
|
|
2018
Q4 | – | Sell |
-9,038
| Closed | -$3.65M | – | 933 |
|
|
2018
Q3 | $3.65M | Buy |
9,038
+2,003
| +28% | +$762K | 0.14% | 134 |
|
|
2018
Q2 | $2.43M | Buy |
7,035
+1,258
| +22% | +$393K | 0.11% | 202 |
|
|
2018
Q1 | $1.99M | Buy |
5,777
+874
| +18% | +$304K | 0.11% | 201 |
|
|
2017
Q4 | $1.84M | Buy |
4,903
+1,516
| +45% | +$614K | 0.13% | 170 |
|
|
2017
Q3 | $1.51M | Buy |
3,387
+434
| +15% | +$207K | 0.13% | 132 |
|
|
2017
Q2 | $1.45M | Buy |
2,953
+362
| +14% | +$158K | 0.14% | 115 |
|
|
2017
Q1 | $1M | Buy |
2,591
+122
| +5% | +$45.2K | 0.12% | 169 |
|
|
2016
Q4 | $906K | Sell |
2,469
-50
| -2% | -$19K | 0.13% | 145 |
|
|
2016
Q3 | $1.01M | Sell |
2,519
-104
| -4% | -$41.7K | 0.15% | 99 |
|
|
2016
Q2 | $916K | Sell |
2,623
-66
| -2% | -$25.4K | 0.14% | 115 |
|
|
2016
Q1 | $970K | Buy |
2,689
+99
| +4% | +$40.8K | 0.22% | 92 |
|
|
2015
Q4 | $1.41M | Buy |
+2,590
| New | +$1.4M | 0.33% | 61 |
|
Other funds holding REGN
VCM
N
Pacer Advisors's REGN Position: Q1 2026 in Review
Pacer Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 9.8% in Q1 2026, selling an estimated $29.9M and leaving 358,633 shares worth $277M. The position accounts for 0.78% of the portfolio, ranked #31.
Pacer Advisors first reported a position in REGN in Q4 2015 and has held it in 41 quarters since. The position peaked at $307M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Pacer Advisors held 358,633 shares of Regeneron Pharmaceuticals worth $277M as of Q1 2026.
- Pacer Advisors sold 39,033 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $29.9M.
- Regeneron Pharmaceuticals made up 0.78% of Pacer Advisors's portfolio in Q1 2026, its #31 holding.
- Pacer Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2015 and has held it in 41 quarters since.
- Pacer Advisors's Regeneron Pharmaceuticals position peaked at $307M in Q4 2025.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.